Bruton's tyrosine kinase inhibitors and their clinical potential in the treatment of B-cell malignancies: focus on ibrutinib

被引：54

作者：

Aalipour, Amin ^{[1
]}

Advani, Ranjana H. ^{[1
]}

机构：

[1] Stanford Univ, Med Ctr, 875 Blake Wilbur Dr,Suite CC-2338, Stanford, CA 94305 USA

来源：

THERAPEUTIC ADVANCES IN HEMATOLOGY | 2014年 / 5卷 / 04期

关键词：

B-cell receptor signaling; Bruton's tyrosine kinase; chronic lymphocytic leukemia; ibrutinib; mantle cell lymphoma; refractory non-Hodgkin's lymphoma;

D O I：

10.1177/2040620714539906

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Aberrant signaling of the B-cell receptor pathway has been linked to the development and maintenance of B-cell malignancies. Bruton's tyrosine kinase (BTK), a protein early in this pathway, has emerged as a new therapeutic target in a variety of such malignancies. Ibrutinib, the most clinically advanced small molecule inhibitor of BTK, has demonstrated impressive tolerability and activity in a range of B-cell lymphomas which led to its recent approval for relapsed mantle cell lymphoma and chronic lymphocytic leukemia. This review focuses on the preclinical and clinical development of ibrutinib and discusses its therapeutic potential.

引用

收藏

页码：121 / 133

页数：13

相关论文

共 69 条

[1] Bruton tyrosine kinase inhibitors: a promising novel targeted treatment for B cell lymphomas [J].

Aalipour, Amin ;

Advani, Ranjana H. .

BRITISH JOURNAL OF HAEMATOLOGY, 2013, 163 (04) :436-443

[2] Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies [J].

Advani, Ranjana H. ;

Buggy, Joseph J. ;

Sharman, Jeff P. ;

Smith, Sonali M. ;

Boyd, Thomas E. ;

Grant, Barbara ;

Kolibaba, Kathryn S. ;

Furman, Richard R. ;

Rodriguez, Sara ;

Chang, Betty Y. ;

Sukbuntherng, Juthamas ;

Izumi, Raquel ;

Hamdy, Ahmed ;

Hedrick, Eric ;

Fowler, Nathan H. .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (01) :88-94

[3] Ibrutinib and novel BTK inhibitors in clinical development [J].

Akinleye, Akintunde ;

Chen, Yamei ;

Mukhi, Nikhil ;

Song, Yongping ;

Liu, Delong .

JOURNAL OF HEMATOLOGY & ONCOLOGY, 2013, 6

[4] Phase II Study of Dasatinib in Relapsed or Refractory Chronic Lymphocytic Leukemia [J].

Amrein, Philip C. ;

Attar, Eyal C. ;

Takvorian, Tak ;

Hochberg, Ephraim P. ;

Ballen, Karen K. ;

Leahy, Kathleen M. ;

Fisher, David C. ;

LaCasce, Ann S. ;

Jacobsen, Eric D. ;

Armand, Philippe ;

Hasserjian, Robert P. ;

Werner, Lillian ;

Neuberg, Donna ;

Brown, Jennifer R. .

CLINICAL CANCER RESEARCH, 2011, 17 (09) :2977-2986

[5] Two targets for the price of one [J].

Ansell, Stephen M. .

BLOOD, 2013, 122 (15) :2529-2531

[6] Lupus Increases The Incidence Ratio Of Hematologic Malignancies: A Meta-Analysis Of Cohort Studies [J].

Apor, Emmanuel ;

O'Brien, Jennifer ;

Stephen, Merin M. ;

Castillo, Jorge J. .

BLOOD, 2013, 122 (21)

[7] Combinatorial drug screening identifies synergistic co-targeting of Bruton's tyrosine kinase and the proteasome in mantle cell lymphoma [J].

Axelrod, M. ;

Ou, Z. ;

Brett, L. K. ;

Zhang, L. ;

Lopez, E. R. ;

Tamayo, A. T. ;

Gordon, V. ;

Ford, R. J. ;

Williams, M. E. ;

Pham, L. V. ;

Weber, M. J. ;

Wang, M. L. .

LEUKEMIA, 2014, 28 (02) :407-410

[8] Ibrutinib: a novel Bruton's tyrosine kinase inhibitor with outstanding responses in patients with chronic lymphocytic leukemia [J].

Barrientos, Jacqueline ;

Rai, Kanti .

LEUKEMIA & LYMPHOMA, 2013, 54 (08) :1817-1820

[9]

Benito JM, 2012, BLOOD, V120

[10] The Promising Impact of Ibrutinib, a Bruton's Tyrosine Kinase Inhibitor, for the Management of Lymphoid Malignancies [J].

Bhatt, Valkal ;

Alejandro, Linh ;

Michael, Angela ;

Ganetsky, Alex .

PHARMACOTHERAPY, 2014, 34 (03) :303-314

← 1 2 3 4 5 6 7 →